Friday, July 25, 2014

Immune Design Flat After IPO

Seattle-based biotechnology company Immune Design is trading flat on the second day after its IPO, after debuting at $12.00 per share. The company priced at the low end of its earlier, estimated IPO range of $12.00 to $14.00 per share. Immune Design is developing treatments for cancer. The company is now trading as IMDZ on the NASDAQ GLobal Market; the biotech is venture backed by The Column Group, Topspin Partners, Alta Partners, Versant Ventures, Osage Partners, ProQuest Investments, as well as Sanofi-Genzyme BioVentures.